MedTrace Logo

Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM

NCT01958528 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 52

Last updated 2022-05-20

No results posted yet for this study

Summary

This is a prospective study to collect blood and bone marrow samples from patients with SM and MGUS. About 100 subjects will be enrolled at the University of Pennsylvania and followed for 2 years. The primary objective of this study is to evaluate CMMCs as a biomarker to detect patients at high risk of progression to multiple myeloma in patients with MGUS and SMM.

Conditions

  • a Diagnosis of MGUS or SMM by IMWG Criteria

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Alfred Garfall, MD · Abramson Cancer Center at Penn Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-23
Primary Completion
2019-01-11
Completion
2019-01-22

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01958528 on ClinicalTrials.gov